Sobajima Mituso, Imamura Teruhiko, Fukuo Atsuko, Ueno Yohei, Onoda Hiroshi, Ueno Hiroshi, Kinugawa Koichiro
The Second Department of Internal Medicine, Graduate School of Medicine, University of Toyama, Toyama, Japan.
J Cardiol Cases. 2023 Mar 1;27(3):132-135. doi: 10.1016/j.jccase.2022.12.002. eCollection 2023 Mar.
The endovascular treatment using a drug-coated balloon (DCB) reduces restenosis and target vessel re-vascularization rate in patients with peripheral artery disease such as claudication and chronic limb-threatening ischemia (CLTI). However, its safety and efficacy in patients with post-below-knee amputation remain unknown. We had a patient with CLTI and a history of below-knee amputation, who suffered a no-flow phenomenon following DCB angioplasty that required above-knee amputation. DCB angioplasty might not be appropriate for those with severe CLTI and histories of amputation.
The present report describes the risk of endovascular treatment using a drug-coated balloon for chronic limb-threatening ischemia patients with a below-knee amputated limb.
使用药物涂层球囊(DCB)进行血管内治疗可降低外周动脉疾病(如间歇性跛行和慢性肢体威胁性缺血(CLTI))患者的再狭窄率和靶血管再血管化率。然而,其在膝下截肢患者中的安全性和有效性尚不清楚。我们有一名患有CLTI且有膝下截肢病史的患者,在DCB血管成形术后出现无血流现象,需要进行膝上截肢。DCB血管成形术可能不适用于患有严重CLTI和截肢病史的患者。
本报告描述了使用药物涂层球囊对患有膝下截肢肢体的慢性肢体威胁性缺血患者进行血管内治疗的风险。